Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
2.450
-0.270 (-9.93%)
At close: Nov 20, 2026, 4:00 PM EST
2.509
+0.058 (2.39%)
After-hours: Nov 20, 2026, 7:59 PM EST
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 600 employees as of December 31, 2025. The number of employees decreased by 200 or 25.00% compared to the previous year. That makes Recursion Pharmaceuticals the 18,725th largest employer in the world and 2,535th in the United States.
Employees
600
Change (1Y)
-200
Growth (1Y)
-25.00%
Revenue / Employee
$113,720
Profits / Employee
-$792,778
Market Cap
1.53B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -200 | -25.00% |
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Sep 30, 2024 | 500 | -50 | -9.09% |
| Jun 30, 2024 | 500 | -50 | -9.09% |
| Mar 31, 2024 | 500 | 0 | - |
| Dec 31, 2023 | 500 | 0 | - |
| Sep 30, 2023 | 550 | 50 | 10.00% |
| Jun 30, 2023 | 550 | 100 | 22.22% |
| Mar 31, 2023 | 500 | 50 | 11.11% |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Sep 30, 2022 | 500 | 170 | 51.52% |
| Jun 30, 2022 | 450 | 180 | 66.67% |
| Mar 31, 2022 | 450 | 232 | 106.42% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Sep 30, 2021 | 330 | -1 | -0.30% |
| Jun 30, 2021 | 270 | - | - |
| Mar 31, 2021 | 218 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Agios Pharmaceuticals | 540 |
| Replimune Group | 465 |
| Vir Biotechnology | 367 |
| UroGen Pharma | 300 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Maze Therapeutics | 141 |
RXRX News
- 2 days ago - Recursion Pharmaceuticals Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Recursion Pharmaceuticals price target lowered to $5.60 from $5.90 at Morgan Stanley - TheFly
- 3 days ago - Recursion Pharmaceuticals aligns with FDA on trial of REC-4881 - TheFly
- 3 days ago - Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis - GlobeNewsWire
- 4 days ago - Recursion Pharmaceuticals price target lowered to $7 from $10 at JPMorgan - TheFly
- 9 days ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Recursion Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 17 days ago - Recursion Pharmaceuticals Earnings release: Q3 2026 - Filings